Phenotypic discovery of GABAA receptor-mediated general anesthetics with analgesic activity
In the authors' words
Abstract General anesthetics are essential for invasive medical procedures; however, there remains a need for safer agents. Using a bespoke 96-well-plate format platform enabling high-throughput imaging of larval zebrafish behavior, we screen 12,000 compounds and identify an isoxazole chemotype that phenocopies the intravenous anesthetics etomidate and propofol. Its optimization via medicinal chemistry yields an anesthetic that we call nidradine. This anesthetic is efficacious in both zebrafish and mice and lacks the problematic adrenal suppression characteristic of etomidate. Mechanistic studies using electrophysiology and structural biology reveal that nidradine, like etomidate and propofol, is a positive allosteric modulator of the GABA A receptor. Remarkably, behavioral assays in mice demonstrate that nidradine differs from most general anesthetics in that it also produces analgesia at subsedative doses.
In plain words AI summary
The researchers screened 12,000 compounds using a high-throughput imaging platform with larval zebrafish. They identified an isoxazole chemotype that mimics the anesthetics etomidate and propofol. Through medicinal chemistry optimization, they developed an anesthetic called nidradine. Nidradine works in both zebrafish and mice and does not cause the adrenal suppression that etomidate causes. Like etomidate and propofol, nidradine enhances GABA A receptor activity. Unlike most general anesthetics, nidradine also relieves pain at doses below those that cause sedation.
Written by Kimi K2.5 using only the abstract above. Jev checked that every sentence is supported by the abstract sentences it cites, and removed any that were not. Point at a sentence to highlight its source.
Appeared: Wednesday, November 18. Nature Communications. Peer-reviewed journal.